Last update 29 Nov 2024
TIN816
Last update 29 Nov 2024
Overview
Basic Info
Drug Type Biological products |
Synonyms TIN 816, TIN-816 |
Target |
Mechanism ATP modulators(ATP modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with TIN816一项旨在评估单次静脉输注TIN816治疗脓毒症相关急性肾损伤（SA-AKI）受试者的安全性和疗效的多中心、随机、双盲、安慰剂对照、四臂、平行组、剂量探索IIb期研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled, four-arm, parallel-group, dose-finding Phase IIb study to evaluate the safety and efficacy of a single intravenous infusion of TIN816 in subjects with sepsis-associated acute kidney injury (SA-AKI)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Four-arm, Parallel-group, Dose-finding Phase 2b Study to Investigate the Safety and Efficacy of TIN816 Via a Single Intravenous Infusion in the Treatment of Participants With Sepsis-associated Acute Kidney Injury (SA-AKI)
A Phase 1, randomized, participant- and investigatorblinded, placebo-controlled, single ascending dose study to investigate the safety, tolerability and pharmacokinetics of TIN816 in Japanese healthy participants
100 Clinical Results associated with TIN816
Login to view more data
100 Translational Medicine associated with TIN816
Login to view more data
100 Patents (Medical) associated with TIN816
Login to view more data
100 Deals associated with TIN816
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Kidney Injury | Phase 2 | AR | 03 Mar 2023 | |
| Acute Kidney Injury | Phase 2 | CZ | 03 Mar 2023 | |
| Acute Kidney Injury | Phase 2 | EE | 03 Mar 2023 | |
| Acute Kidney Injury | Phase 2 | LT | 03 Mar 2023 | |
| Acute Kidney Injury | Phase 2 | SG | 03 Mar 2023 | |
| Acute Kidney Injury | Phase 2 | TW | 03 Mar 2023 | |
| Acute kidney injury due to sepsis | Phase 2 | BE | 22 Nov 2022 | |
| Acute kidney injury due to sepsis | Phase 2 | FR | 22 Nov 2022 | |
| Acute kidney injury due to sepsis | Phase 2 | DE | 22 Nov 2022 | |
| Acute kidney injury due to sepsis | Phase 2 | HU | 22 Nov 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free